First Cases of Sexually Transmitted Ringworm Reported in the U.S.
By Physician’s Briefing Staff HealthDay Reporter
THURSDAY, Oct. 31, 2024 -- Doctors in New York City are chronicling the first known U.S. cases of sexually transmitted ringworm (Trichophyton mentagrophytes).
Until now, transmission of the fungal infection through skin-to-skin sexual contact has been rare, although cases have been reported in Southeast Asia and France since 2021, researchers reported. These have been a subtype of T. mentagrophytes called TMVII.
The new report, published in the Oct. 31 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, states that the first U.S. case of sexually transmitted TMVII was reported in June, and "four additional TMVII infections were diagnosed during April-July 2024 in New York City among men who have sex with men."
The rash appeared "on the [patients'] face, buttocks, or genitals, and was successfully treated with antifungal medications," said a team led by dermatologist Avrom Caplan, M.D., of NYU Langone Health in New York City.
According to the report, all five cases of sexually transmitted ringworm so far documented in the United States involved gay or bisexual men in their 30s who had multiple sex partners.
It is unclear how TMVII make its way to the United States, although the man whose case of fungal infection was reported in June said he had recently traveled to several countries in Europe. All five patients had reported recent sexual contact with other men. In all five cases, common antifungal medications cleared up the patients' rashes.
The bottom line for clinicians, as well as sexually active people: Be aware "that TMVII can spread through sexual contact and cause lesions on the genitals, buttocks, face, trunk, or extremities," Caplan's team said.
They noted that only lab tests can confirm T. mentagrophytes infection, which some people may initially mistake for "eczema, psoriasis, or other dermatologic conditions."
The infection can be treated and cured, but takes time. According to the researchers, "patients might require oral antifungal therapy for up to 3 months and should take the treatment until lesions have fully resolved." That is important, because as long as the rash is present, infected people must avoid skin-to-skin contact with others to avoid passing the infection on. They should also avoid sharing personal items, Caplan and team said. Finally, they added, patients should resist the urge to use steroid antifungal creams to treat the rash, since these can "worsen tinea [ringworm] infection."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Prior Military Sexual Trauma Linked to Late-Life Suicide Attempt
THURSDAY, May 1, 2025 -- Prior military sexual trauma (MST) is associated with late-life suicide attempt and death by suicide or overdose, according to a study published online...
Antibiotic Noninferior to Ceftriaxone + Azithromycin for Gonorrhea
MONDAY, April 21, 2025 -- For uncomplicated urogenital gonorrhea, gepotidacin, which inhibits bacterial DNA replication, is noninferior to ceftriaxone plus azithromycin, according...
Treating Male Partners Reduces Recurrence in Bacterial Vaginosis
MONDAY, March 10, 2025 -- Treating male partners in addition to women with bacterial vaginosis results in a lower rate of recurrence than treating only women, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.